QurAlis NEWS

An Appalachian odyssey: Hunting for ALS genes along a sprawling family tree

August 7, 2018

The man had come for a third opinion. Other doctors had told him he had amyotrophic lateral sclerosis, or ALS, a neuromuscular disease that causes progressive paralysis, but he didn’t…

With a Strong Focus on ALS Patients, Mitsubishi Tanabe Pharma America Works to Increase Access and Foster Development With Quralis

June 1, 2018

Click here to go to the article.

Discovery Advances

May 22, 2018

We successfully generated a crystal structure of one of our early lead molecules in complex with our molecular target. This structure is currently being used to design new compounds.

QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria, united in the fight to cure ALS

April 5, 2018

CAMBRIDGE, Mass., April 5, 2018. QurAlis Corporation, a new private biotech company focused on developing precision solutions to cure ALS, today announced the addition of biotech investors MP Healthcare Venture…

QurAlis has won the Amgen Golden Ticket at LabCentral

December 15, 2017

CAMBRIDGE, Mass., Dec. 15, 2017 QurAlis was chosen by an Amgen internal committee and live audience members at a “Quick Pitch” event hosted by Amgen at its Cambridge R&D and Operations…